-
公开(公告)号：US10227565B2
公开(公告)日：2019-03-12
申请号：US15361900
申请日：2016-11-28
申请人： The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone , The Regents of the University of California
发明人： Saiyong Zhu , Sheng Ding , Holger Willenbring , Milad Rezvani , Jack Harbell
IPC分类号： A61K38/18 , C12N5/071 , A61K31/506 , A61K31/661 , A61K31/19 , A61K31/135 , A61K31/405 , A61K31/4709 , A61K31/573 , A61K35/407 , A61K45/06
摘要： Compositions and methods are described herein for inducing reprogramming of non-pluripotent cells across lineage and differentiation boundaries to generate endodermal progenitor cells and hepatocytes. Compositions and methods for expansion of endodermal progenitor cells without loss of phenotype are also described herein.
-
公开(公告)号：US11332716B2
公开(公告)日：2022-05-17
申请号：US15747729
申请日：2016-07-26
申请人： The Regents of the University of California , The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
发明人： Matthias Hebrok , Holger Andreas Russ , Sheng Ding , Saiyong Zhu
摘要： Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.
-
公开(公告)号：US11241455B2
公开(公告)日：2022-02-08
申请号：US16066659
申请日：2017-01-12
发明人： Tao Xu , Sheng Ding
IPC分类号： A61K35/17 , A61K31/133 , A61K31/42 , A61K31/223 , A61K31/195 , A61K31/225 , A61K31/197 , A61P37/06 , A61P35/00 , A61P29/00 , A61K38/20 , A61K38/21
摘要： Provided herein are methods for treating an individual for a disease (e.g., an autoimmune disease or a cancer) using an active agent which affects metabolism of α-ketoglutarate (α-KG) and/or 2-hydroxyglutarate (2-HG) in differentiating T cells. In some embodiments, a Got1 inhibitor is used to generate a population of T cells enriched in peripheral regulatory T (iTreg) cells, which population enriched in iTreg cells may find use in treating an autoimmune disease. In some embodiments, a TCA cycle-associated metabolite, or a derivative thereof, is used to generate a population of T cells in enriched in IL-17- and IL-17F-producing CD4 T (TH17) cells, which population enriched in TH17 cells may find use in treating a cancer.
-
公开(公告)号：US12104169B2
公开(公告)日：2024-10-01
申请号：US17587116
申请日：2022-01-28
发明人： Mingliang Zhang , Sheng Ding
IPC分类号： C12N5/0793 , A61K35/30
CPC分类号： C12N5/0619 , A61K35/30 , C12N2501/065 , C12N2501/115 , C12N2501/15 , C12N2501/155 , C12N2501/385 , C12N2501/415 , C12N2501/999 , C12N2506/1307
摘要： Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become neuronal cells.
-
公开(公告)号：US10849904B2
公开(公告)日：2020-12-01
申请号：US16447764
申请日：2019-06-20
申请人： University of Washington , The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone
发明人： Thomas A. Reh , Paul Nakamura , Sheng Ding
IPC分类号： A61K31/519 , C07D495/04 , A61K31/426 , A61K9/00 , A61P27/02
摘要： Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
-
公开(公告)号：US10144915B2
公开(公告)日：2018-12-04
申请号：US15030911
申请日：2014-10-23
发明人： Haixia Wang , Sheng Ding
摘要： Compositions and methods are described herein for chemically inducing cells that express a single pluripotency transcription factor to change their differentiation state and become cardiac cells, cardiac progenitor cells, cardiomyocytes, or a combination thereof.
-
公开(公告)号：US09982231B2
公开(公告)日：2018-05-29
申请号：US15066312
申请日：2016-03-10
发明人： Nan Cao , Sheng Ding
IPC分类号： A61L27/38 , C12N5/077 , A61K45/06 , A61K31/404 , A61K31/416 , A61K31/4409 , A61K31/4709 , A61K31/506 , A61K31/519 , A61K31/551 , A61K31/192 , A61K31/437 , A61K35/34
CPC分类号： C12N5/0657 , A61K31/192 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/4409 , A61K31/4709 , A61K31/506 , A61K31/519 , A61K31/551 , A61K35/34 , A61K45/06 , A61L27/3826 , A61L27/3895 , A61L2430/20 , C12N2501/065 , C12N2501/11 , C12N2501/135 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/415 , C12N2501/603 , C12N2501/72 , C12N2501/727 , C12N2501/998 , C12N2501/999 , C12N2506/1307 , A61K2300/00
摘要： Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become cardiac progenitor cells or cardiomyocytes.
-
公开(公告)号：US09512406B2
公开(公告)日：2016-12-06
申请号：US14578377
申请日：2014-12-20
发明人： Saiyong Zhu , Sheng Ding , Holger Willenbring , Milad Rezvani , Jack Harbell
IPC分类号： C12N5/071 , A61K35/407 , A61K31/506 , A61K31/661 , A61K31/19 , A61K31/135 , A61K31/405 , A61K31/4709 , A61K31/573 , A61K45/06
CPC分类号： C12N5/067 , A61K31/135 , A61K31/19 , A61K31/405 , A61K31/4709 , A61K31/506 , A61K31/573 , A61K31/661 , A61K35/407 , A61K38/18 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1875 , A61K45/06 , C12N2501/065 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/12 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/237 , C12N2501/38 , C12N2501/415 , C12N2501/42 , C12N2501/72 , C12N2506/02 , C12N2506/1307 , C12N2506/45 , A61K2300/00
摘要： Compositions and methods are described herein for inducing reprogramming of non-pluripotent cells across lineage and differentiation boundaries to generate endodermal progenitor cells and hepatocytes. Compositions and methods for expansion of endodermal progenitor cells without loss of phenotype are also described herein.
摘要翻译： 本文描述的组合物和方法用于诱导非多能细胞跨越谱系和分化边界的重新编程以产生内胚层祖细胞和肝细胞。 本文还描述了用于扩增内胚层祖细胞而不丧失表型的组合物和方法。
-
公开(公告)号：US09909104B2
公开(公告)日：2018-03-06
申请号：US14907056
申请日：2014-07-25
发明人： Sheng Ding , Ke Li , Saiyong Zhu
CPC分类号： C12N5/0678 , A61K35/39 , C12N5/0676 , C12N5/0696 , C12N2500/38 , C12N2501/11 , C12N2501/115 , C12N2501/117 , C12N2501/119 , C12N2501/15 , C12N2501/16 , C12N2501/385 , C12N2501/40 , C12N2501/41 , C12N2501/415 , C12N2501/999 , C12N2506/02 , C12N2506/1307
摘要： Compositions and methods of producing mammalian cell populations that include a high proportion of definitive endoderm cells, posterior foregut-like progenitor cells, pancreatic progenitor cells and/or pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes.
-
公开(公告)号：US20180216076A1
公开(公告)日：2018-08-02
申请号：US15747729
申请日：2016-07-26
发明人： Matthias Hebrok , Holger Andreas Russ , Sheng Ding , Saiyong Zhu
CPC分类号： C12N5/0677 , A01K67/0271 , A61K35/00 , A61K35/39 , A61P3/10 , C12N5/0676 , C12N5/0678 , C12N2500/22 , C12N2500/33 , C12N2500/38 , C12N2501/11 , C12N2501/117 , C12N2501/155 , C12N2501/375 , C12N2501/395 , C12N2501/727 , C12N2501/91 , C12N2501/999 , C12N2506/02 , C12N2506/22 , C12N2513/00
摘要： Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.056 秒)
